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Introduction
Manufacturing processes for therapeutic monoclonal
antibodies (mAbs) have evolved immensely in the past
two decades around two major thrust areas.
1) Advancements in a) Cell line development-
breakthrough and incremental knowledge gain in tech-
nology b) Media and feed formulation strategies c)
Advent of Disposables and Instrumentation technolo-
gies thus offering significant improvements to Process
Development (PD).
2) Establishment of platform processes to leverage fas-
ter PD [1,2].
A platform process generally consists of a standard i)
Cell line development technique, ii) Basal medium and
feeds, iii) Process parameters and scale-up approach.
The biggest advantage of using the platform process for
the PD group is in expediting the project timelines. The
platform approach also benefits from well-established
and validated work flows in Manufacturing, QA, QC
and Supply-chain groups.
Certain disadvantages have also been cited for the
platform approach. For example, modifications in the
platform process are generally discouraged due to time,
cost and efforts required in accommodating such
changes. Also, as process conditions can substantially
impact the product quality (PQ) attributes, a platform
approach does not allow any significant changes in the
PQ attributes, if desired.
Materials and methods
In this study, CHO cell lines were cultured in chemically
defined medium. Experiments were carried out in 2L stir-
red tank bioreactors and 125mL shake flasks running at
140 rpm in 5% CO2 controlled incubator shaker. Cell
count and viability were determined using haemocyt-
ometer. Lactate, glucose, osmolality and IgG concentra-
tion was also estimated along with glycosylation profiling.
Results and discussion
Case 1: Multiple cell lines developed using same
technology expressing different mAbs
Using the same cloning technology, cell lines expressing
mAbs 1-4 were developed. These cell lines when run
with the platform process showed very similar growth,
titer and glycosylation profiles. Glycan profile thus pro-
duced is represented as three species; type I, II and III.
The advantage of platform process was evident from
the similarity of glycan profiles achieved in all the mAbs
run with this process. However, for mAbs 3 and 4, the
target glycan profile was significantly different. The plat-
form process gave 20-30% higher glycan type 1 than the
respective targets. In order to match the targeted glycan
profile, a few changes were made:
i) mAb 3: New feed introduced to reduce glycan
type 1; feeding strategy was optimized during PD.
ii) mAb 4: In addition to feeding strategy used for
mAb3, changes in process parameter (pH and DO)
set-points were done to achieve desired glycosylation
profiles.
Case 2: Difference in lead clone selection criteria - growth
vs. specific productivity
Clone selection is done by ranking the clones based on
parameters such as cell growth, titer, specific productiv-
ity (PCD) and PQ. In this study, the lead clones were
shortlisted based on different strategies. For mAbs 1-4,
the lead clone was shortlisted based on cell growth and* Correspondence: rohit.diwakar@biocon.com
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titer as dominant selection criteria. For mAbs 5 and 6,
PCD was the dominant selection criterion. The other
aspects of the cloning technique were same in all cell
lines.
When lead clones for mAb 5 and 6 were run in plat-
form process they showed poor growth characteristics
(Figure 1a). The early drop in viability made these
clones unfit for a manufacturing process. Changes in the
platform process were attempted to overcome this man-
ufacturing concern:
i) mAb 5: Culture longevity was increased by
restricting cell growth. This was achieved by redu-
cing nutrient levels in the production medium.
ii) mAb 6: Lactate and ammonia accumulation was
reduced by optimizing medium/feed composition
and pH, DO control ranges.
The modified processes significantly improved the cul-
ture longevity and viability profiles, making them suita-
ble for manufacturing (Figure 1b).
Case 3: Cell lines expressing the same mAb developed
using different technology
Two cloning technologies, 1 and 2 were used to develop
clones expressing the same mAb. The major differences
in the technologies were i) host cell lines ii) design of
vector and its mechanism in the genome. Both cell lines
were run with the same platform process and a two-fold
difference in cell count was observed between them
(Figure 1c). The lactate levels were also markedly differ-
ent (Figure 1d), possibly indicating differences in nutri-
ent metabolism. The lactate differences also reflected in
the pH profiles.
Summary
Case 1: The use of platform process enabled accelerated
PD from cell culture perspective. However, accommo-
dating the specific PQ requirements resulted in
extended process development, affecting timelines.
Case 2: Change in clone selection criteria was
observed to significantly impact culture performance
while applying platform process. This almost resulted in
Figure 1 (Clockwise direction) a) Viability comparison between control (mAb1-4) and mAb5 and 6. b) Viability comparison between
platform and modified process for mAb5 and 6. c) Cell count comparison and d) Lactate comparison between cell line technology 1 and 2. As
expected, PQ profiles between these two clones were very different.
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rejection of these clones, thus extending PD timelines.
This was prevented by modifying the platform process.
Case 3: Clones developed using different cloning tech-
nologies when run with the platform process resulted in
different cell culture and PQ profiles. Therefore, the
type of cloning technique forms an integral part of the
platform process.
Though platform process was not suitable in most of
the cases discussed here, it still offers advantages like
expedited project timelines and established work flows.
These benefits were achieved by establishing four ver-
sions of the platform process to meet the varied cell cul-
ture and PQ requirements. Based on the cell line
characteristics and target PQ profiles, the appropriate
version is chosen to initiate PD. These versions retained
the major advantages of the platform process such as
having common media and feeds with only changes in
their concentrations and set point of main process para-
meters to achieve desired PQ.
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